Strategies and Resources for Overcoming Barriers to CAR T-Cell Therapy
August 23rd 2024Acute lymphoblastic leukemia specialists explore resources and strategies to address the logistical hurdles of CAR-T therapy implementation, while also examining patient support programs designed to enhance treatment accessibility and adherence.
Read More
Treatment Approaches with Consolidation and Maintenance Post CAR T-cell Therapy
August 8th 2024The panel examines their strategies for consolidation or maintenance treatment following CAR T-cell therapy, while also considering whether CAR T-cell therapy can function as a standalone treatment modality.
Read More
Expert Perspectives on the Potential Impact of Obe-cel on the Treatment Landscape for R/R ALL
August 1st 2024The panel explores the potential impact of obecabtagene autoleucel on the treatment landscape and decision-making process for acute lymphoblastic leukemia, contingent upon its FDA approval.
Read More
Translating Data Updates from FELIX and ZUMA-3 to the Clinical Practice Setting
August 1st 2024A medical expert reviews the FELIX study, highlighting its key findings and characteristics while comparing and contrasting it with the ZUMA-3 trial in the context of CAR T-cell therapy for acute lymphoblastic leukemia.
Read More
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
July 18th 2024The panel evaluates key patient characteristics and clinical factors influencing the decision to recommend CAR T-cell therapy as a treatment option in relapsed or refractory acute lymphoblastic leukemia.
Read More
Navigating CAR T-cell Therapy in R/R ALL: Expert Perspectives
July 11th 2024The panel examines the current positioning of CAR T-cell therapy within the treatment paradigm for Relapsed / Refractory Acute Lymphoblastic Leukemia, considering the distinctions between Philadelphia chromosome-positive and negative patients.
Read More
CAR T-cell Therapy: Mechanisms of Actions of Brexucabtagene Autoleucel and Obecabtagene Autoleucel
June 27th 2024Dr. Lori Muffly explains the general mechanism of action in CAR T-cell therapy and compares the distinct features of Brexucabtagene autoleucel (Brexu-cel), Tisagenlecleucel (Tisa-cel), and Obecabtagene autoleucel (Obe-cel).
Read More
Dr Jabbour on the Efficacy of Ponatinib in Newly Diagnosed Ph+ ALL
June 9th 2023Elias Jabbour, MD, discusses efficacy data from the phase 3 PhALLCON trial of ponatinib plus reduced-intensity chemotherapy vs imatinib plus reduced-intensity chemotherapy in newly diagnosed patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.
Read More
Gaining Ground in Gynecologic and Hematologic Cancers at ASCO 2023: Drs Herrera, Westin, and Jabbour
June 5th 2023OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.
Read More